Tandem Diabetes Care (TNDM) falls 2.69% on Strong Volume January 14

Equities Staff  |

Today, Tandem Diabetes Care Inc Inc’s (NASDAQ: TNDM) stock fell $3.34, accounting for a 2.69% decrease. Tandem Diabetes Care opened at $123.00 before trading between $124.51 and $116.81 throughout Friday’s session. The activity saw Tandem Diabetes Care’s market cap fall to $7,672,210,784 on 977,044 shares -above their 30-day average of 572,582.

Tandem Diabetes Care employs around 1600 people with a head office in San Diego, California.

About Tandem Diabetes Care Inc

Tandem Diabetes Care, Inc. is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem's flagship product, the t:slim X2™ insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in San Diego, California.

Visit Tandem Diabetes Care Inc's profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Tandem Diabetes Care Inc and to follow the company's latest updates, you can visit the company's profile page here: Tandem Diabetes Care Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Commodities Post Strongest Gains in Over a Decade
Charlie Munger Doubles Down on Alibaba While the Fed Signals Tightening
Commodities — Assessing 2021 and Forecasting 2022



Market Movers

Sponsored Financial Content